Research Article

Prognostic Value of CD133 and SOX2 in Advanced Cancer

Table 2

Subgroup analyses of CD133 positivity in overall survival (OS).

FactorsSubgroupsStudiesHR with 95% CIHeterogeneity (P)P valueCasesTSA

Tumor typeColorectal cancer61.27 (0.64-2.50)< 0.0010.493848
Ovarian cancer23.27 (0.43-25.03)0.0490.254152
Melanoma11.1 (0.34-3.8)NA> 0.0532
Cancer with bone metastases19.73 (1.08-87.49)NA< 0.0550More
Gastric cancer12.097 (1.003-4.383)NA< 0.05100More
Study sourceJapanese40.90 (0.36-2.26)0.0010.823421
Chinese42.12 (1.35-3.33)0.1540.001579More
Others32.07 (0.90-4.78)0.2290.089182
Survival rate5 years31.26 (0.38-4.17)0.0010.703307
< 3 years210.92 (2.44-48.96)0.8880.00279More
Others61.38 (0.85-2.26)0.010.197796
Sample typeTissue91.51 (0.92-2.49)< 0.0010.1031100
Blood22.68 (0.33-21.83)0.0880.35882
Age (years)> 6022.09 (1.20-3.64)0.9890.009238More
≤ 6031.40 (0.31-6.27)0.010.661149
NA61.64 (0.92-2.91)0.0030.093795
Treatment regimensAdjuvant therapy41.91 (1.08-3.39)0.1730.026309More
Surgery and adjuvant therapy61.34 (0.62-2.93)< 0.0010.457781
Testing methodBlind31.64 (0.32-8.37)< 0.0010.553455
NA81.62 (1.00-2.63)0.0050.048727More
Study center designMulticentre22.74 (0.46-16.19)0.0970.266173
Single-center81.54 (0.85-2.79)< 0.0010.154977
NA11.1 (0.34-3.8)NA> 0.0532
Sample size≥ 10061.58 (0.97-2.57)0.0070.066891
 < 10051.93 (0.66-5.65)0.0010.232291

HR: hazard ratio; 95% CI: 95% confidence interval; NA: not applicable; TSA: trial sequential analysis.